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Objectives: The goal of this study was to assess mitochondrial function, energy, and 
purine metabolism, protein synthesis machinery from the nucleolus to the ribosome, 
inflammation, and expression of newly identified ectopic olfactory receptors (ORs) and 
taste receptors (TASRs) in the frontal cortex of typical cases of dementia with Lewy 
bodies (DLB) and cases with rapid clinical course (rpDLB: 2 years or less) compared with 
middle-aged non-affected individuals, in order to learn about the biochemical abnormal-
ities underlying Lewy body pathology.
Methods: Real-time quantitative PCR, mitochondrial enzymatic assays, and analysis of 
β-amyloid, tau, and synuclein species were used.
results: The main alterations in DLB and rpDLB, which are more marked in the rapidly 
progressive forms, include (i) deregulated expression of several mRNAs and proteins of 
mitochondrial subunits, and reduced activity of complexes I, II, III, and IV of the mito-
chondrial respiratory chain; (ii) reduced expression of selected molecules involved in 
energy metabolism and increased expression of enzymes involved in purine metabolism; 
(iii) abnormal expression of nucleolar proteins, rRNA18S, genes encoding ribosomal pro-
teins, and initiation factors of the transcription at the ribosome; (iv) discrete inflammation; 
and (v) marked deregulation of brain ORs and TASRs, respectively. Severe mitochondrial 
dysfunction involving activity of four complexes, minimal inflammatory responses, and 
dramatic altered expression of ORs and TASRs discriminate DLB from Alzheimer’s dis-
ease. Altered solubility and aggregation of α-synuclein, increased β-amyloid bound to 
membranes, and absence of soluble tau oligomers are common in DLB and rpDLB. Low 
levels of soluble β-amyloid are found in DLB. However, increased soluble β-amyloid 1–40 
and β-amyloid 1–42, and increased TNFα mRNA and protein expression, distinguish 
rpDLB.
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inTrODUcTiOn
Dementia with Lewy bodies (DLB) is the second most common 
neurodegenerative dementia in the elderly, clinically manifested 
by fluctuating cognition with pronounced variation in attention 
and alertness, recurrent visual hallucinations which are typically 
well formed and detailed, and spontaneous motor features of 
parkinsonism; repeated falls, syncope, transient loss of conscious-
ness, systematized delusions, hallucinations in other modalities, 
and neuroleptic sensitivity are not uncommon (1–4). These 
symptoms are preceded by rapid eye movement sleep behavior 
disorder, psychiatric symptoms, loss of smell, and dysautonomia, 
together with occipital hypo-metabolism, hallucinations, and 
cognitive impairment (5, 6).
Dementia with Lewy bodies is pathologically characterized by 
Lewy bodies and Lewy neurites in the brainstem, limbic system, 
and cortical areas (2, 7, 8). The main pathological change is the 
production and accumulation, in Lewy bodies and neurites, of 
abnormal α-synuclein, which is phosphorylated, nitrated, and 
truncated, has abnormal solubility, prompts the production of oli-
gomeric species, aggregates into fibrils and is ubiquitinated (9–19). 
For these reasons, DLB is classified among α-synucleinopathies 
with Lewy bodies or Lewy body diseases (LBDs), together with 
Parkinson’s disease (PD) (11). Other changes in DLB are neuron 
loss, microvacuolation, and Alzheimer’s disease (AD) pathology 
distinguished by β-amyloid deposition in the form of diffuse and 
senile plaques, as well as early changes of neurofibrillary tangle 
(NFT) pathology (8).
Whether the amount of α-synuclein pathology (i.e., Lewy 
bodies and neurites) in cerebral cortex is predictable of dementia 
in LBDs is a matter of controversy (20–23). Cholinergic and 
dopaminergic denervation of the neocortex probably accounts at 
least in part for cognitive deficits in LBDs (24–29). Concomitant 
pathologies have also been suggested to explain variations in the 
degree of cognitive impairment in DLB (30–32).
However, deficits in neurotransmission are not limited to 
dopaminergic and cholinergic systems. Synapses are primarily 
damaged in the neocortex in DLB (33–38). Synaptic damage is 
probably related to toxic α-synuclein oligomers and pore forma-
tion (39, 40). Moreover, synaptic alterations are accompanied 
by abnormalities in neurotransmitter signaling (41, 42) in a way 
similar to that reported in other α-synucleinopathies (43–45).
Additional molecular alterations converge in the pathogenesis 
of DLB, including impaired autophagy and ubiquitin-proteasome 
system of protein (46–50), as well as altered responses to pro-
tein misfolding (51). Preliminary studies have shown impaired 
mitochondrial activity and oxidative damage involving proteins, 
lipids, and DNA in the neocortex in DLB (52, 53); α-synuclein 
is one of the targets of oxidative damage in the frontal cortex in 
DLB (54).
The average survival time for typical DLB from the beginning 
of symptoms is about 5–8 years (55). However, some cases have 
a rapid course and are considered clinically to be in the group of 
rapidly progressive dementias (56, 57). DLB with rapid progres-
sion has been named rapid DLB (rpDLB) (55, 58). The mean 
duration of rpDLB is about 9 months; delirium, visual hallucina-
tions, delusions, and fluctuating cognitive impairment, followed 
by parkinsonism and myoclonus, are the predominant symptoms 
(58).
Our hypothesis is that alterations of several metabolic path-
ways converge in the pathogenesis of DLB and that impaired 
mitochondria and energy metabolism, purine metabolism, pro-
tein synthesis, and inflammation may be important factors in the 
pathogenesis of DLB. In the same line, although neuropathologi-
cal studies have not shown differences between DLB and rpDLB 
(58), biochemical alterations probably discriminate between DLB 
and rpDLB.
The present DLB-centered study was undertaken to analyze 
(i) levels of selected mRNAs and proteins of subunits of the five 
mitochondrial complexes and genes linked to energy metabolism; 
(ii) expression of genes encoding enzymes involved in purine 
metabolism; (iii) mRNA and protein expression of selected 
nucleolar proteins, rRNAs, and genes encoding ribosomal 
proteins, and protein expression of initiation and elongation fac-
tors of protein transcription at the ribosome; (iv) cytokines and 
mediators of the inflammatory response; and (v) gene expression 
of particular brain receptors involved in olfaction and taste known 
to be altered in other neurodegenerative diseases with abnormal 
protein aggregates. All these pathways were assessed in the frontal 
cortex of cases with typical course (DLB) and in cases with rapid 
course (rpDLB) compared with middle-aged (MA) individuals to 
identify molecular factors linked to Lewy body pathology.
MaTerials anD MeThODs
human cases
Brain tissue was obtained from the Institute of Neuropathology 
HUB-ICO-IDIBELL Biobank and the Hospital Clinic-IDIBAPS 
Biobank following the guidelines of Spanish legislation on this 
matter (Real Decreto de Biobancos 1716/2011) and approval of 
the local ethics committees. Processing of brain tissue has been 
detailed elsewhere (59, 60). The postmortem interval between 
death and tissue processing was between 3 and 15.30 h. One hemi-
sphere was immediately cut in coronal sections, 1 cm thick, and 
selected areas of the encephalon were rapidly dissected, frozen on 
conclusion: Molecular alterations in frontal cortex in DLB involve key biochemical 
pathways such as mitochondria and energy metabolism, protein synthesis, purine 
metabolism, among others and are accompanied by discrete innate inflammatory 
response.
Keywords: dementia with lewy bodies, alzheimer’s disease, α-synuclein, mitochondria, protein synthesis, 
inflammation, β-amyloid, olfactory receptors
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metal plates over dry ice, placed in individual air-tight plastic bags 
and stored at −80°C until use for biochemical studies. The other 
hemisphere was fixed by immersion in 4% buffered formalin for 
3 weeks for morphological studies. Neuropathological diagnosis 
in all cases was based on the routine study of 20 selected de-waxed 
paraffin sections of representative regions of the cerebral cortex, 
diencephalon, thalamus, brain stem, and cerebellum, which were 
stained with hematoxylin and eosin, and Klüver-Barrera, or pro-
cessed for immunohistochemistry for microglia (antibodies Iba1 
and CD68), glial fibrillary acidic protein, β-amyloid with antibod-
ies Aβ clone 6 F/3D (diluted 1:50, Dako, Carpinteria, CA, USA), 
Aβ40 (diluted 1:100, Merck Millipore, Billerica, MA, USA), and 
Aβ42 (diluted 1:50, Merck Millipore), phospho-tau (clone AT8), 
α-synuclein, TDP-43, ubiquitin, and p62 using EnVision + System 
peroxidase (Dako), and diaminobenzidine and H2O2. DLB cases 
(n = 13) were neuropathologically categorized following current 
staging classifications for LBD (22, 61, 62), stages of of NFT 
pathology (21, 63), and phases of AD-related β-amyloid plaques 
(64), and a final ABC score was assigned according to current 
consensus guidelines (65). Neuropathological data were scored 
by two independent observers. Based on clinical criteria DLB 
cases were categorized as typical DLB (DLB, n = 9: eight men, 
one woman, age 76.4 ± 5.7 years) or rapid DLB (rpDLB, n = 4, 
two men and two women, age 73.7 ±  2.2) on the basis of the 
natural clinical course. rpDLB here was defined as 2 years or less 
of disease duration from the first symptom to death (58). Cases 
with associated pathologies such as vascular diseases excepting 
mild atherosclerosis and arteriolosclerosis, TDP-43 proteinopa-
thy, infections of the nervous system, brain neoplasms, systemic 
and central immune diseases, metabolic syndrome, and hypoxia 
were excluded from the present study. MA cases (n = 12: seven 
men and five women, age 59.9 ± 15.59) had not suffered from 
neurologic, psychiatric, or metabolic diseases (including meta-
bolic syndrome) and did not have abnormalities in the neuro-
pathological examination excepting stages I–II of NFT pathology 
and phases 1–2 of β-amyloid plaques.
Quantification of β-amyloid burden was carried out with a 
Nikon Eclipse E800 microscope (4× objective; Nikon Imaging 
Inc., Tokyo, Japan). The cortical total Aβ burden was calculated as 
the percentage of the area of Aβ deposition in plaques with respect 
to the total area in 9–10 pictures taken at random from frontal 
cortex in every case. β-Amyloid quantification was assessed using 
the Adobe Photoshop CS5 software (Adobe Systems Inc., San 
Jose, CA, USA).
A summary of cases is shown in Table 1.
rna Purification
Purification of RNA from the right frontal cortex area 8 was car-
ried out using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, 
Germany) following the protocol provided by the manufacturer 
combined with DNase digestion to avoid extraction and later 
amplification of genomic DNA. The concentration of each sample 
was obtained from A260 measurements with NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). 
RNA integrity was tested using the Agilent 2100 BioAnalyzer 
(Agilent, Santa Clara, CA, USA) (66). Values of RNA integrity 
number (RIN) are shown in Table 1. Special care was taken to 
assess pre-mortem and postmortem factors, which may interfere 
with RNA processing (67).
Bivariate analyses were carried out to detect association of our 
variables with potential confounding factors (age, postmortem 
delay, and RIN) using Spearman or Pearson correlations for 
quantitative variables. Stastical analysis was performed with 
GraphPad Prism version 5.00 and SPSS 19. Postmortem delay 
had no effect on RIN values in the present series.
retrotranscription reaction
Retrotranscription reaction of RNA samples was carried out 
with the High-Capacity cDNA Archive kit (Applied Biosystems, 
Foster City, CA, USA) following the guidelines provided by the 
supplier, and using Gene Amp® 9700 PCR System thermocycler 
(Applied Biosystems). A parallel reaction for one RNA sample 
was processed in the absence of reverse transcriptase to rule out 
DNA contamination.
real-time Pcr
Real-time quantitative PCR (RT-qPCR) assays were conducted 
in duplicate on 1,000 ηg of cDNA samples obtained from the 
retrotranscription reaction, diluted 1:20 in 384-well optical plates 
(Kisker Biotech, Steinfurt, GE) utilizing the ABI Prism 7900 
HT Sequence Detection System (Applied Biosystems). Parallel 
amplification reactions were carried out using 20× TaqMan 
Gene Expression Assays and 2× TaqMan Universal PCR Master 
Mix (Applied Biosystems) (66). Genes analyzed with the cor-
responding abbreviations and TaqMan probes used in the study 
are shown in Table 2.
The selection of probes was based on criteria covering a 
larger project geared to analyzing similar expression of the 
same molecules related to inflammation, mitochondria, energy 
metabolism, purine metabolism, protein synthesis and selected 
receptors in several diseases including AD, PD, Creutzfeldt-
Jakob’s disease, certain tauopathies, in addition to DLB, in all 
cases using the same probes and methods in an attempt to learn 
about commonalities and differences among these diseases in 
a particular brain region. Our idea is that all these pathways 
are altered in most neurodegenerative diseases with abnormal 
protein aggregates, but alterations are region-, stage-, and 
disease-specific.
Parallel assays for each sample were carried out using 
β-glucuronidase (GUS-β), X-prolyl aminopeptidase (ami-
nopeptidase P) 1 (XPNPEP1), AARS (alanyl-transfer RNA 
synthase), and HPRT (hypoxanthine-guanine phospho-
ribosyltransferase) probes for normalization. The selection 
of these housekeeping genes was based on previous data 
showing low vulnerability in the brain of several human 
neurodegenerative diseases (68, 69). The reactions were 
performed using the following parameters: 50°C for 2  min, 
95°C for 10  min, 40 cycles at 95°C for 15  s, and 60°C for 
1 min. TaqMan PCR data were captured using the Sequence 
Detection Software (SDS version 2.2, Applied Biosystems). 
Subsequently, threshold cycle (CT) data for each sample 
were analyzed with the double-delta CT (ΔΔCT) method 
(66). First, delta CT (ΔCT) values were calculated as the 
normalized CT values for each target gene in relation to the 
TaBle 1 | summary of cases used in the present study.
no Diagnosis gender age PM delay rin Pcr WB elisa Ma Mi
1 MA Male 64 8 h 30 min 7.7 X X X
2 MA Male 56 5 h 7.1 X X X X X
3 MA Male 67 5 h 7 X X X X
4 MA Male 62 3 h 7.2 X X X X X
5 MA Male 52 4 h 40 min 7.9 X X X X
6 MA Male 30 4 h 10 min 8.4 X X X X
7 MA Male 53 3 h 7.7 X X X X
8 MA Female 49 7 h 8.2 X X X
9 MA Female 75 3 h 6.5 X X X
10 MA Female 46 9 h 35 min 7.2 X X X X
11 MA Female 86 4 h 15 min 8.4 X X X
12 MA Female 79 3 h 35 min 8 X X X
13 DLB Male 81 7 h 5.3 X X X
14 DLB Female 78 5 h 5.7 X X X X
15 DLB Male 76 5 h 10 min 5.2 X X X X
16 DLB Male 83 9 h 5.2 X X X X X
17 DLB Male 78 8 h 30 min 6.3 X X X
18 DLB Male 64 8 h 15 min 7 X X X X
19 DLB Male 80 8 h 6.1 X X X X
20 DLB Male 77 7 h 20 min 6.4 X X X
21 DLB Male 71 9 h 7 X X X X
22 rpDLB Female 75 13 h 30 min 5.6 X X X X X
23 rpDLB Male 76 6 h 30 min 5.5 X X X X X
24 rpDLB Male 71 5 h 5 X X X X X
25 rpDLB Female 73 15 h 30 min 6.1 X X X X
MA, middle-aged cases with no neurological disease and neuropathological lesions limited to Alzheimer’s disease-related pathology stages I–II/0–A of Braak and phases 1–2 of 
β-amyloid plaques; mean age ± SD was 59.92 ± 15.60. DLB cases were older with no differences between DLB (76.44 ± 5.77) and rpDLB (73.75 ± 2.22). DLB, the term DLB 
is used to name clinically and neuropathologically verified dementia with Lewy bodies, whereas rpDLB indicates DLB with rapid course. PM delay, postmortem delay; RIN, RNA 
integrity number; PCR, implies the use of these samples for gene expression studies; WB, cases analyzed with western blotting; ELISA, enzyme-linked immunosorbent assay; MA, 
mitochondrial enzyme activities; MI, study of α-synuclein oligomeric species in total homogenate fractions. RIN median: 7. Ratio RIN min/max: 5/8.4. PM delay median: 6 h 30 m. 
PM delay: min/max: 3/15 h 30 m.
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mean values of GUS-β, XPNPEP1, AARS, and HPRT. Second, 
ΔΔCT values were obtained with the ΔCT of each sample 
minus the mean ΔCT of the population of control samples 
(calibrator samples). The fold change was determined using 
the equation 2−ΔΔCT.
gel electrophoresis and Western Blotting 
from Total homogenate
Tissue was processed as reported elsewhere (66). A total of 0.1 g of 
tissue of samples from frontal cortex area 8 were lysed with a glass 
homogenizer in Mila lysis buffer (0.5M Tris at pH 7.4 containing 
0.5 methylenediaminetetraacetic acid at pH 8.0, 5M NaCl, 0.5% 
Na deoxycholic acid, 0.5% Non-idet P-40, 1 mM phenylmethyl-
sulfonyl fluoride, bi-distilled water, and protease and phosphatase 
inhibitor cocktails (Roche Molecular Systems, Pleasanton, CA, 
USA)), and then centrifuged for 15  min at 13,000  rpm at 4°C 
(Ultracentrifuge Beckman with 70Ti rotor, CA, USA). Protein 
concentration was measured with SmartspectTMplus spectro-
photometer (Bio-Rad, CA, USA) using the Bradford method 
(Merck, Darmstadt, Germany). Samples containing 15  µg of 
protein and the standard Precision Plus ProteinTM Dual Color 
(Bio-Rad) were loaded onto 10–15% acrylamide gels. Proteins 
were separated with sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrophoretically transferred 
to nitrocellulose membranes using the Trans-Blot®TurboTM 
transfer system (Bio-Rad) at 200  mA/membrane for 40  min. 
Non-specific bindings were blocked by incubation with 5% milk 
in Tris-buffered saline (TBS) containing 0.1% Tween for 1 h at 
room temperature. After washing, the membranes were incu-
bated at 4°C overnight with one of the primary antibodies (Table 
S1 in Supplementary Material) in TBS containing 3% albumin 
and 0.1% Tween. These membranes were incubated for 1 h with 
the appropriate HRP-conjugated secondary antibody (1:2,000, 
Dako, Glostrup, Denmark), and the immune complexes were 
revealed with a chemiluminescence reagent (ECL, Amersham, 
GE Healthcare, Buckinghamshire, UK). Monoclonal anti-β-actin 
antibody diluted 1:30,000 (β-Actin, A5316; Sigma-Aldrich, St. 
Louis, MO, USA) was blotted to control protein loading.
Mitochondrial enzymatic activities
The activities of mitochondrial complexes I, II, III, IV, and V were 
analyzed using commercial kits following the manufacturers’ 
instructions (mitochondrial complex I, II, IV, and V: Novagen, 
Merck Biosciences, Darmstadt, Germany; mitochondrial complex 
III: MyBiosource, CA, USA). Isolation of mitochondria was car-
ried out as reported in detail elsewhere (70). Briefly, mitochondria 
were extracted from frozen human brain tissue (100 mg) under 
ice-cold conditions. Tissues were minced in ice-cold isolation 
buffer (IB), and then homogenized and centrifuged at 1,000 × g 
for 10 min. The supernatant (S1) was conserved. The pellet was 
washed with two volumes of IB and centrifuged again under the 
same conditions. This last supernatant (S2) was combined with S1. 
TaBle 2 | abbreviations, full names, and TaqMan probes used to assess 
gene expression in the frontal cortex of Ma and DlB cases in the present 
study.
gene Full name reference
housekeeping genes
GUS-B β-glucuronidase Hs00939627_m1
XPNPEP1 X-prolylaminopeptidase (aminopeptidase P) 1 Hs00958026_m1
AARS Alanyl-tRNA synthetase Hs00609836_m1
HPRT Hypoxanthine phosphoribosyltransferase 1 Hs_02800695_m1
genes encoding proteins of mitochondria and energy metabolism-
related molecules
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 2, 8 kDa
Hs00159575_m1
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 7, 14.5kDa
Hs01561430_m1
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa
Hs01071117_m1
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 3, 12 kDa
Hs00427185_m1
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7, 18 kDa
Hs00188142_m1
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22 kDa
Hs00605903_m1
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S 
protein 7, 20 kDa
Hs00257018_m1
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S 
protein 8, 23 kDa
Hs00159597_m1
SDHB Succinate dehydrogenase complex, subunit B, 
iron sulfur (Ip)
Hs00268117_m1
UQCRB Ubiquinol-cytochrome c reductase binding 
protein
Hs00559884_m1
UQCR11 Ubiquinol-cytochrome c reductase, complex 
III subunit XI
Hs00907747_m1
COX7A2L Cytochrome c oxidase subunit VIIa polypeptide 
2 like
Hs00190880_m1
COX7C Cytochrome c oxidase subunit VIIc Hs01595220_g1
ATP5D ATP synthase, H+ transporting, mitochondrial 
F1 complex, delta subunit
Hs00961521_m1
ATP5G2 ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit C2 
Hs01096582_m1
ATP5H ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit d
Hs01046892_gH
ATP5L ATP synthase, H+ transporting, mitochondrial 
Fo complex, subunit G
Hs00538946_g1
ATP5O ATP synthase, H+ transporting, mitochondrial 
F1 complex, O subunit
Hs00426889_m1
ATP2B3 ATPase, Ca++ transporting, plasma 
membrane 3
Hs00222625_m1
ATP2B4 ATPase, Ca++ transporting, plasma 
membrane 4
Hs00608066_m1
ATP4A ATPase, H+/K+ exchanging, alpha polypeptide Hs00167575_m1
ATP6V0A1 ATPase, H+ transporting, lysosomal V0  
subunit a1
Hs00193110_m1
ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, 
V0 subunit b
Hs01072388_m1
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, 
V1 subunit H
Hs00977530_m1
FAM82A2 Family with sequence similarity 82, member A2 Hs00216746_m1
5
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gene Full name reference
LHPP Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase
Hs00383379_m1
SLC6A6 Solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6
Hs00161778_m1
SLC25A31 Solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 31
Hs00229864_m1
TOMM40 Translocase of outer mitochondrial membrane 
40 homolog (yeast)
Hs01587378_mH
ZNF642 Zinc finger protein 642 Hs01372953_m1
Purine metabolism genes
ADA Adenosine deaminase Hs01110945_m1
AK1 Adenylate kinase (AK) 1 Hs00176119_m1
AK2 AK 2 Hs01123132_g1
AK4 AK 4 Hs03405743_g1
AK5 AK 5 Hs00952786_m1
AK7 AK 7 Hs00330574_m1
APRT Adenine phosphoribosyltransferase Hs00975725_m1
DGUOK Deoxyguanosine kinase Hs00176514_m1
ENTPD1 Ectonucleoside triphosphate 
diphosphohydrolase 1
Hs00969559_m1
ENTPD2 Ectonucleoside triphosphate 
diphosphohydrolase 2
Hs00154301_m1
ENTPD3 Ectonucleoside triphosphate 
diphosphohydrolase 3
Hs00928977_m1
NME1 Non-metastatic cells 1, protein expressed in 
(nucleoside-diphosphate kinase)
Hs02621161_s1
NME3 Non-metastatic cells 3, protein expressed in 
(nucleoside-diphosphate kinase)
Hs01573874_g1
NME4 Non-metastatic cells 4, protein expressed in 
(nucleoside-diphosphate kinase)
Hs00359037_m1
NME5 Non-metastatic cells 5, protein expressed in 
(nucleoside-diphosphate kinase)
Hs00177499_m1
NME6 Non-metastatic cells 6, protein expressed in 
(nucleoside-diphosphate kinase)
Hs00195083_m1
NME7 Non-metastatic cells 7, protein expressed in 
(nucleoside-diphosphate kinase)
Hs00273690_m1
NT5C 5′, 3′-nucleotidase, cytosolic Hs00274359_m1
NT5E 5′-nucleotidase, ecto (CD73) Hs00159686_m1
PNP Purine nucleoside phosphorylase Hs01002926_m1
POLR3B Polymerase (RNA) III (DNA directed) 
polypeptide B
Hs00932002_m1 
PRUNE Prune homolog (Drosophila) Hs00535700_m1 
nucleolar, rrnas, and genes encoding ribosomal protein
NCL Nucleolin Hs01066668_m1
NPM1 Nucleophosmin (nucleolar phospho-protein 
B23, numatrin)
Hs02339479_m1
NPM3 Nucleophosmin/nucleoplasmin 3 Hs00199625_m1
rRNA 28S RNA, 28S ribosomal 5 Hs03654441_s1
rRNA 18S Eukaryotic 18S rRNA Hs99999901_s1
UBTF Upstream binding transcription factor, RNA 
polymerase I
Hs01115792_g1
RPL5 Ribosomal protein L5 Hs_03044958_g1
RPL7 Ribosomal protein L7 Hs_02596927_g1
RPL21 Ribosomal protein L21 Hs_00823333_s1
TaBle 2 | continued
(Continued) (Continued)
gene Full name reference
RPL22 Ribosomal protein L22 Hs_01865331_s1
RPL23A Ribosomal protein L23A Hs_01921329_g1
RPL26 Ribosomal protein L26 Hs_00864008_m1
RPL27 Ribosomal protein L27 Hs_03044961_g1
RPL30 Ribosomal protein L30 Hs_00265497_m1
RPL31 Ribosomal protein L31 Hs_0101549_g1
RPS3A Ribosomal protein S3A Hs_00832893_sH
RPS5 Ribosomal protein S5 Hs_00734849_g1
RPS6 Ribosomal protein S6 Hs_04195024_g1
RPS10 Ribosomal protein S10 Hs_01652370_gH
RPS13 Ribosomal protein S13 Hs_01011487_g1
RPS16 Ribosomal protein S16 Hs_01598516_g1
RPS17 Ribosomal protein S17 Hs_00734303_g1
cytokines and mediators of the inflammatory responses
C1QL1 Complement component 1, q subcomponent 1 Hs00198578_m1
C1QTNF7 C1q and tumor necrosis factorY related protein 
7
Hs00230467_m1
C3AR1 Complement component 3a receptor 1 Hs00377780_m1
CLEC7A C-type lectin domain family 7, member A Hs01124746_m1
CSF1R Colony-stimulating factor 1 receptor Hs00911250_m1
CSF3R Colony-stimulating factor 1 receptor Hs00167918_m1
CST7 Cystatin F (leukocystatin) Hs00175361_m1
CTSC Cathepsin C Hs00175188_m1
CTSS Cathepsin S Hs00356423_m1
IL1B Interleukin-1B Hs01555410_m1
IL6 Interleukin-6 Hs00985639_m1
IL6ST Interleukin-6 signal transducer Hs00174360_m1
IL8 Interleukin-8 Hs00174103_m1
IL10 Interleukin-10 Hs00961622_m1
IL10RA Interleukin-10 receptor A Hs00155485_m1
IL10RB Interleukin-10 receptor B Hs00609836_m1
TGFA1 Transforming growth factor-A1 Hs00998133_m1
TGFA2 Transforming growth factor-A2 Hs00234244_m1
TLR4 Toll-like receptor 4 Hs01060206_m1
TLR7 Toll-like receptor 7 Hs00152971_m1 
TNF Tumor necrosis factor Hs01113624_m1
TNFRSF1A Tumor necrosis factor receptor superfamily 
member 1a
Hs01042313_m1
Olfactory receptor (Or) and taste receptor (Tasr) genes
OR2D2 OR, family 2, subfamily D, member 2 Hs00999189_s1
OR2J3 OR, family 2, subfamily J, member 3 Hs01943871_g1
OR2L13 OR, family 2, subfamily L, member 13 Hs00380097_m1
OR2T1 OR, family 2, subfamily T, member 1 Hs01661970_s1
OR2T33 OR, family 2, subfamily T, member 33 Hs04230793_gH
OR4F4 OR, family 4, subfamily F, member 4 Hs03406040_gH
OR6F1 OR, family 6, subfamily F, member 1 Hs01054972_s1
OR10G8 OR, family 10, subfamily G, member 8 Hs01943074_g1
OR11H1 OR, family 11, subfamily H, member 1 Hs03406084_gH
OR51E1 OR, family 51, subfamily E, member 1 Hs02339849_s1
OR52H1 OR, family 52, subfamily H, member 1 Hs01661724_s1
OR52L1 OR, family 52, subfamily L, member 1 Hs02339119_g1
OR52M1 OR, family 52, subfamily M, member 1 Hs01098608_s1
TaBle 2 | continued TaBle 2 | continued
gene Full name reference
TAS2R4 TASR, type 2, member 4 Hs00249946_s1
TAS2R5 TASR, type 2, member 5 Hs01549633_s1
TAS2R10 TASR, type 2, member 10 Hs00256794_s1
TAS2R13 TASR, type 2, member 13 Hs01059805_s1
TAS2R14 TASR, type 2, member 14 Hs00256800_s1
TAS2R50 TASR, type 2, member 50 Hs00604351_s1
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Centrifugation at 10,000 × g for 10  min at 4°C resulted in the 
mitochondria-enriched pellet. The pellet was finally re-suspended 
in one volume of IB and stored at −80°C. Protein concentration 
was measured by Smartspect™ plus spectrophotometer (Bio-
Rad, CA, USA) using the Bradford method (Merck, Darmstadt, 
Germany). Twenty-five micrograms of mitochondria was loaded 
into each well. Activity of citrate synthase was evaluated following 
validated protocols (71) with slight modifications. The activity of 
citrate synthase was determined as the rate of reduction of DTNB 
[5′, 5′-dithiobis (2-nitrobenzoic acid)] to thionitrobenzoic acid 
at 412 nm. For this purpose, 25 µg of mitochondria was added 
to a 1ml mixture containing 500  µl of Tris (200mM, pH 8.0) 
with Triton X-100 [0.2% (vol/vol)], 100 µl of DTNB, and 30 µl 
of 10mM Acetyl CoA, and then the final volume was adjusted to 
950 l with distilled water. The reaction was started by the addi-
tion of 50 l of 10 mM oxalacetic acid. The increase in absorbance 
at 412 nm was read for 3 min at room temperature with a DU 
800UV/Visible spectrophotometer (Beckman Coulter, CA, USA) 
in 1 ml polystyrene or methacrylate cuvettes (72).
concentration of β-amyloid 1–40 (aβ40) 
and β-amyloid 1–42 (aβ42)
Frozen brain samples were homogenized in TBS buffer composed 
of 140 mM NaCl, 3 mM KCl, 25 mM Tris–HCl pH 7.4, and 5 mM 
ethylene-diamine-tetra-acetic acid (EDTA) with a cocktail of 
protease inhibitors (Roche Molecular Systems, Pleasanton, CA, 
USA), and ultra-centrifuged at 100,000 × g for 1 h at 4°C. The 
supernatant was the soluble fraction used for amyloid quantifica-
tion, and the protein of this fraction was measured with BCA. 
The detection and measurement of β-amyloid 1–40 (Aβ40) and 
β-amyloid 1–42 (Aβ42) were carried out by enzyme-linked 
immune-absorbent assay with the corresponding detection kits 
(Invitrogen, Camarillo, CA, USA), following the instructions of 
the supplier. TBS-soluble Aβ40 and Aβ42 levels were normalized 
to the total amount of protein from each individual sample (73).
Quantification of Membrane-associated 
β-amyloid
Frozen samples were homogenized in TBS with a cocktail of 
protease and phosphatase inhibitors (Roche Molecular Systems). 
Homogenates were centrifuged at 14,000 × g for 30 min at 4°C. 
The pellet was re-suspended in 2% SDS and centrifuged at 
14,000 × g for 30 min at 4°C. The supernatant was membrane-
associated Aβ and the protein of this fraction was measured 
with BCA method (Thermo Scientific, USA). Proteins were (Continued)
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separated in SDS-polyacrylamide gel electrophoresis. Thirty-
five micrograms of protein was loaded onto a precast NuPAGE 
4–12% Bis-Tris gel system (Invitrogen, MA, USA) with MES 
buffer (Invitrogen, MA, USA). The proteins were transferred 
to nitrocellulose membranes, 200  mA/membrane, for 90  min. 
Then membranes were boiled with PBS 1× for 15 min, and non-
specific bindings were blocked by incubation in 5% non-fat dry 
milk in TBS containing 0.2% Tween for 1 h at room temperature. 
After washing, the membranes were incubated at 4°C overnight 
with primary antibodies to human amyloid-beta protein, clone: 
4G8 (1:500, Signet, MA, USA) and 6E10 (1:2,000, Covance, NJ, 
USA) in TBS containing 5% albumin and 0.2% Tween. After 
washing, the membranes were incubated at 4°C overnight with 
the primary antibody to human amyloid-beta protein, clone: 
4G8 (1:500, Signet, MA, USA) in TBS containing 5% albumin 
and 0.2% Tween. Membranes were then incubated for 1 h with 
the appropriate HRP-conjugated secondary antibody (1:2,000, 
Dako, DK), and the immune complexes were visualized with a 
chemiluminescence reagent (ECL, Amersham, GB). β-Actin was 
used as a control of protein loading (73). Using this protocol, 
membrane-enriched fractions may also contain small amounts 
of TBS-soluble β-amyloid.
Oligomeric Tau species
Frozen samples were homogenized in lysis buffer: 100 mM Tris 
(pH 7.0), 100 mM NaCl, 10 mM EDTA, 0.5% NP-40, and 0.5% 
sodium deoxycholate plus protease and phosphatase inhibitors 
(Roche Molecular Systems). After centrifugation at 14,000 ×  g 
for 20  min at 4°C (Ultracentrifuge Beckman with 70Ti rotor), 
supernatants were quantified for protein concentration (BCA), 
mixed with SDS-PAGE sample buffer, boiled, and separated to 8% 
SDS-PAGE gels. The proteins were transferred to nitrocellulose 
membranes, 200  mA/membrane, for 90  min. The membranes 
were blocked with 5% non-fat milk in TBS containing 0.2% Tween 
for 1 h at room temperature. After washing, the membranes were 
incubated at 4°C overnight with the primary antibody anti-tau-5 
(1:1,000, Thermo-Fisher, MA, USA) in TBS containing 5% 
albumin and 0.2% Tween. Membranes were then incubated for 
1  h with the HRP-conjugated secondary anti-mouse antibody 
(1:2,000, Dako, DK), and the immune complexes were visualized 
with ECL. β-Actin was used as a control of protein loading (74). 
No attempt was made to analyze sarkosyl-insoluble fractions as 
oligomeric tau species are visualized with the utilized protocol 
and the identification of tau bands was not an objective of the 
present study.
α-synuclein Oligomeric species in Total 
homogenate Fractions
Frozen samples were homogenized in a glass homogenizer, in 
750 μl of ice-cold PBS+ (sodium phosphate buffer pH 7.0, plus 
protease inhibitors), sonicated, and centrifuged at 2,700 ×  g 
at 4°C for 10 min. The pellet was discarded and the resulting 
supernatant was ultra-centrifuged at 43,000 × g at 4°C for 1 h. 
The supernatant (S2) was kept as the PBS-soluble fraction. The 
resulting pellet was re-suspended in a solution of PBS, pH 7.0, 
containing 0.5% sodium deoxycholate, 1% Triton and 0.1% 
SDS, and this was ultra-centrifuged at 43,000 × g at 4°C for 1 h. 
The resulting supernatant (S3) was kept as the deoxycholate-
soluble fraction. The corresponding pellet was re-suspended 
in a solution of 2% SDS in PBS and maintained at room tem-
perature for 30 min. Afterward, the samples were centrifuged 
at 133,000 ×  g at 25°C for 1  h and the resulting supernatant 
(S4) was the SDS-soluble fraction. Equal amounts of each frac-
tion were mixed with reducing sample buffer and processed 
in parallel for 10% SDS-PAGE electrophoresis and western 
blotting. Membranes were incubated with anti-α-synuclein 
oligomer-specific antibody (Agrisera, Vännäs, Sweden) at a 
dilution of 1:1,000. The protein bands were visualized with the 
ECL method (66).
statistical analysis
The normality of distribution of the mean fold-change values 
obtained by RT-qPCR for every region and stage between con-
trols and DLB cases was analyzed with the Kolmogorov–Smirnov 
test. The non-parametric Kruskal–Wallis test was performed to 
compare groups when the samples did not follow a normal distri-
bution, whereas the one-way ANOVA with post hoc Tukey’s range 
test for multiple comparisons was used for normal variables. 
Statistical analysis was performed with GraphPad Prism version 
5.01 (La Jolla, CA, USA) and Statgraphics Statistical Analysis 
and Data Visualization Software version 5.1 (Warrenton, VA, 
USA). Differences between groups were considered statistically 
significant at p-values: *p < 0.05, **p < 0.01, and ***p < 0.001.
Because of the large number of parameters and regions ana-
lyzed, multiple comparison tests and false discovery rate might 
be employed (75, 76). However, due to the limited number of 
cases, the possibility to obtain significant results minimizes 
(77). Therefore, present quantitative results must be considered 
exploratory.
Densitometry of western blot bands was assessed with the 
TotalLab program (TotalLab Quant, Newcastle, UK) and then sub-
sequently analyzed with GraphPad Prism, Statgraphics Statistical 
Analysis and Data Visualization Software version 5.1 (VA, USA) 
by one-way ANOVA with post hoc Tukey’s range test for multiple 
comparisons. Differences were considered statistically significant 
at p-values: *p < 0.05, **p < 0.01, and ***p < 0.001.
The enzymatic activities for each mitochondrial complex were 
expressed as a rate of nanomoles per minute per milligram of 
mitochondrial protein per protein concentration normalized with 
the mitochondrial complex activity rate of citrate synthase activ-
ity. Data were presented as mean ± SEM for all the experiments. 
All the data were analyzed with Student’s t-test using GraphPad 
Prism version 5.01 (La Jolla, CA, USA) and Statgraphics Statistical 
Analysis and Data Visualization Software version 5.1 (Warrenton, 
VA, USA). In all experimental procedures the significance level 
was set at *p < 0.05, **p < 0.01, and ***p < 0.001.
resUlTs
general neuropathological Findings
Brain weight and neuropathological characteristics in the frontal 
cortex including neuron loss, astrocytic gliosis, microgliosis, 
spongiosis, diffuse plaques, senile plaques, β-amyloid angiopathy, 
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and α-synuclein aggregates (Lewy bodies and Lewy neurites) 
were assessed in DLB and rpDLB cases. Thal phase of β-amyloid 
deposition, Braak stages of NFT pathology, CERAD global, ABC 
classification, and LBD stage were also considered to frame AD- 
and LBD-related pathology in every case. Results are summarized 
in Table 3. A remarkable observation was the discrete microglial 
response, as revealed with Iba1 and CD68 antibodies, in the 
frontal cortex in DLB and rpDLB.
No differences in the amount of fibrillar β-amyloid, consider-
ing diffuse and senile plaques, were observed between the two 
groups; the total plaque burden varied from absent to frequent 
in both groups. The average percentage of Aβ40 of the total 
β-amyloid in plaques was 7.24% in DLB and 6.03% in rpDLB, 
and the percentage of Aβ42 was 68.49% in DLB and 67.70% in 
rpDLB. NFT pathology varied from stage I to stage VI in DLB and 
from stage 0 to stage V in rpDLB. NFTs in frontal cortex occurred 
in two DLB and two rpDLB cases.
Astrocytic gliosis was variable from one case to another and 
varied from mild to moderate in DLB and rpDLB excepting one 
DLB in which astrocytic gliosis was considered severe.
A remarkable observation was the discrete microglial response, 
as revealed with Iba1 and CD68 antibodies, in the frontal cortex 
in DLB and rpDLB.
Neuropathological findings are summarized in Table 3.
mrna expression levels of selected 
Mitochondrial subunits and energy 
Metabolism-related Molecules in Ma, 
DlB, and rpDlB
The expression levels of five of twenty-seven genes analyzed 
was deregulated in DLB when compared with MA cases 
including increase expression of ATP5G2 and ATP5H involved 
in mitochondrial complex (p <  0.05). Deregulation of energy 
metabolism genes included decrease in ATP6VOB and increase 
in ATP4A and SLC6A6 (p < 0.05). Regarding rpDLB, the expres-
sion levels of ATP6VOB and TOMM40, involved in energy 
metabolism, was decreased in rpDLB (p < 0.01 and p < 0.05, 
respectively) (Table 4). Since the trend of altered gene expres-
sion was in the same direction in DLB and rpDLB, no significant 
differences were observed when comparing DLB and rpDLB 
(Table 4).
Protein expression of Mitochondrial 
subunits of the respiratory chain in Ma, 
DlB, and rpDlB
Western blots showed marked alterations in DLB when compared 
with MA cases. The expression levels of complex I subunits 
NDUFA7, NDUFA10, NDUFB10, and NDUFB8 were significantly 
reduced (p ranging from <0.05 to <0.001) when compared with 
MA cases and using β-actin for protein normalization, expression 
of which was maintained in DLB and rpDLB when compared 
with MA cases. NDUFS8 protein expression was not modified in 
DLB when compared with MA. Protein levels of SDHB (complex 
II), UQCRC2 (complex III), MTCO1 (complex IV), and ATP5A 
and ATP50 (complex V) were also significantly decreased in DLB 
when compared with MA (p <  0.05) using β-actin for protein 
loading normalization (Figure  1). In contrast, only NDUFA7 
was significantly reduced in rpDLB when compared with MA 
(p < 0.01). However, the expression of several subunits showed a 
trend toward decrease in rpDLB; therefore, significant differences 
between DLB and rpDLB were restricted to NDUFB8, SDHB, 
ATP5A, and ATP50 (p < 0.01) (Figure 1).
Voltage dependent anion channel (VDAC) expression was 
reduced in DLB and less markedly in rpDLB when compared 
with MA thus suggesting a reduced number of mitochondria 
or reduced mitochondria size. Nevertheless, NDUFA10, 
NDUFB10, NDUFB8, UQCRC2, MTCO1, and AT5A pro-
tein expression was also reduced in DLB cases when using 
VDAC for normalization (p ranging from <0.05 to <0.001). 
NDUFA7, NDUFS8, and ATP50 levels were similar in DLB 
and MA cases using VDAC for normalization. Curiously, 
expression levels of all the assessed subunits were preserved 
in rpDLB when normalized with VDAC. As a result, levels of 
NDUFA10, NDUFB10, NDUFB8, SDHB, UQCRC2, ATP5A, 
and ATP50 were significantly higher in rpDLB when com-
pared with DLB (p values ranging from <0.05 to <0.001) 
(Figure 1).
activity of Mitochondrial complexes i, ii, 
iii, iV, and V in Frontal cortex area 8 in 
DlB and rpDlB cases
Significant decrease in the activity of complexes I, II, III, and IV 
was detected in frontal cortex area 8 in DLB and rpDLB when 
compared with MA cases and normalized with the ratio of citrate 
synthase activity (p  <  0.05) (Figure  2). No differences were 
observed when comparing DLB and rpDLB cases. The activity 
of complex V showed a trend toward decrease in DLB and more 
clearly in rpDLB but without statistical significance (Figure 2).
mrna expression of genes involved in 
Purine Metabolism in Ma, DlB, and rpDlB
The expression of all the assessed genes involved in purine 
metabolism was altered in the same direction in DLB and 
rpDLB when compared with MA cases. Changes were greater 
in rpDLB than in DLB. ADA, AK1, ENTPD1, NME6, and PNP 
(p < 0.05); NME1, NME3, NME4 (all of them with p < 0.01) and 
PRUNE (p < 0.001) were upregulated in rpDLB when compared 
with MA cases (Table 5). Finally, three genes, ENTPD2, NME3, 
and PRUNE were significantly upregulated in rpDLB when 
compared with DLB (p values varied from <0.05 to <0.001) 
(Table 5).
mrna expression levels of genes 
encoding nucleolar Proteins and 
ribosomal Proteins, and rrnas18s and 
28s in Ma, DlB, and rpDlB
Nucleoplasmin 1 (NPM1) mRNA was significantly decreased in 
DLB when compared with MA (p < 0.05) (Table 6).
rRNA 18S expression was increased in rpDLB (p  <  0.01) 
when compared with MA and also when compared with DLB 
(p < 0.01) (Table 6).
TaBle 3 | summary of the main neuropathological findings of Ma (cases 1–12), DlB (cases 13–21), and rpDlB cases (cases 22–25) in the present series.
case Brain 
weight
rDlB N loss astrocytosis Microglia spongiosis Diffuse 
plaques
senile 
plaques
P-tau lewy 
bodies
Thal 
phase
neurofibrillary 
tangle Braak 
stage 
ceraD aBc lewy body 
diseases 
stage
1 NA – Absent Absent Absent Absent Absent Absent Isolated Absent 0 I 0 A0B1C0 0
2 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
3 NA – Absent Absent Absent Absent Absent Absent Isolated Absent 0 II 0 A0B1C0 0
4 NA – Absent Absent Absent Absent Absent Absent Isolated Absent 0 II 0 A0B1C0 0
5 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
6 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
7 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
8 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
9 NA – Absent Absent Absent Absent Rare Rare Isolated Absent 1 III 0 A1B1C0 0
10 NA – Absent Absent Absent Absent Absent Absent Absent Absent 0 0 0 A0B0C0 0
11 NA – Absent Absent Absent Absent Moderate Moderate Sparce Absent 2 IV 0 A2B2C0 0
12 NA – Absent Absent Absent Absent Moderate Moderate Sparce Absent 2 IV 0 A2B2C0 0
13 1,295 – Moderate Moderate Moderate Mild Frequent Moderate Isolated Frequent 4 III Moderate A3B2C2 Neocortical
14 795 – Severe Severe Severe Mild Frequent Frequent Frequent Moderate 5 VI Frequent A3B3C3 Neocortical 
15 1,230 – Mild Mild Mild Mild Frequent Moderate Sparse Moderate 5 V incipient Frequent A3B3C3 Neocortical
16 1,300 – Mild Moderate Moderate Mild Frequent Moderate Moderate Frequent 5 IV Moderate A3B2C2 Neocortical 
17 1,220 – Mild Mild Mild Mild Severe Moderate Sparse Frequent 4 IV Moderate A3B2C2 Neocortical
18 1,370 – Mild Mild Mild Mild Absent Absent Absent Sparse 0 I 0 A0B1C0 Limbic
19 1,280 – Mild Moderate Mild Mild Moderate Moderate Isolated Moderate 3 II Moderate A2B1C2 Neocortical
20 1,365 – Mild Mild Mild Mild Absent Absent Absent Sparse 0 III 0 A0B2C0 Limbic
21 1,300 – Moderate Moderate Moderate Mild Moderate Frequent Isolated Frequent 4 II Moderate A3B1C2 Neocortical
22 1,120 Yes Moderate Moderate Moderate Mild Moderate Moderate Sparse Sparse 4 II Moderate A3B1C2 Limbic
23 1,300 Yes Mild Mild Mild Mild Moderate Moderate Moderate Sparse 5 V Moderate A3B3C2 Limbic
24 1,300 Yes Mild Moderate Moderate Mild Absent Absent Absent Sparse 0 0 0 – Limbic
25 1,240 Yes Mild Mild Mild Mild Moderate Frequent Sparse Frequent 5 V incipient Frequent A3B3C3 Neocortical
NA, not available.
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TaBle 4 | mrna expression of selected subunits of the mitochondrial respiratory chain and genes encoding proteins linked to energy metabolism in 
Ma (n = 12), DlB (n = 9), and rpDlB (n = 4).
Probes Ma DlB rpDlB Ma vs DlB Ma vs rpDlB DlB vs rpDlB
Mitochondria
Complex I NDUFA2 1.02 ± 0.22 1.01 ± 0.09 0.94 ± 0.08 – – –
NDUFA7 1.27 ± 0.58 0.89 ± 0.25 1.00 ± 0.11 – – –
NDUFA10 1.03 ± 0.27 1.11 ± 0.26 1.19 ± 0.31 – – –
NDUFB3 1.02 ± 0.23 0.95 ± 0.24 0.99 ± 0.20 – – –
NDUFB7 1.02 ± 0.23 1.19 ± 0.53 1.25 ± 0.13 – – –
NDUFB10 1.05 ± 0.35 0.87 ± 0.30 1.19 ± 0.20 – – –
NDUFS7 1.09 ± 0.47 0.98 ± 0.26 0.71 ± 0.14 – – –
NDUFS8 1.03 ± 0.25 1.19 ± 0.66 1.64 ± 0.25 – – –
Complex II SDHB 1.05 ± 0.38 0.84 ± 0.16 0.84 ± 0.16 – – –
Complex III UQCRB 1.06 ± 0.40 1.09 ± 0.44 1.00 ± 0.24 – – –
UQCR11 1.02 ± 0.19 1.10 ± 0.26 1.28 ± 0.27 – – –
Complex IV COX7A2L 1.08 ± 0.41 0.93 ± 0.39 1.07 ± 0.38 – – –
COX7C 1.03 ± 0.24 0.89 ± 0.38 0.85 ± 0.24 – – –
Complex V ATP5D 1.03 ± 0.24 0.98 ± 0.18 0.93 ± 0.13 – – –
ATP5G2 1.07 ± 0.42 0.61 ± 0.23 0.69 ± 0.02 *↓ (0.0118) – –
ATP5H 1.02 ± 0.21 0.80 ± 0.18 0.82 ± 0.05 *↓ (0.0281) – –
ATP5L 1.03 ± 0.26 1.00 ± 0.23 1.01 ± 0.06 – – –
ATP5O 1.02 ± 0.18 0.86 ± 0.22 0.95 ± 0.14 – – –
energy metabolism-related molecules
ATP2B3 1.03 ± 0.25 0.99 ± 0.45 1.03 ± 0.33 – – –
ATP2B4 1.01 ± 0.18 0.97 ± 0.27 0.83 ± 0.30 – – –
ATP4A 1.11 ± 0.51 2.15 ± 1.00 1.75 ± 1.24 *↑ (0.0389) – –
ATP6VOB 1.04 ± 0.29 0.72 ± 0.25 0.54 ± 0.10 *↓ (<0.05) **↓ (0.0035) –
FAM82A2 1.02 ± 0.22 1.05 ± 0.09 1.09 ± 0.09 – – –
SLC6A6 1.02 ± 0.19 1.37 ± 0.27 1.39 ± 0.36 *↑ (0.0154) – –
SLC25A3 1.05 ± 0.35 1.09 ± 0.43 1.01 ± 0.19 – – –
TOMM40 1.05 ± 0.38 0.88 ± 0.30 0.56 ± 0.15 – *↓ (0.0486) –
ZNF642 1.02 ± 0.22 0.94 ± 0.32 1.03 ± 0.04 – – –
Similar trends are found in DLB and rpDLB when compared with MA cases. Major changes are represented with the corresponding p-value, and mRNA levels are expressed as 
mean fold change ± SD determined by real-time quantitative PCR (RT-qPCR) and analyzed with the ΔΔthreshold cycle (CT) method: *p < 0.05, **p < 0.01, and ***p < 0.001.
10
Garcia-Esparcia et al. Dementia with Lewy Bodies
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 89
Genes encoding ribosomal proteins of the large (L) and the 
small (S) subunits were upregulated in DLB when compared 
with MA control cases including RPL7, RPL21, RPL30, and RPS5 
(p values varied from <0.05 to <0.001), but RPL22 was down-
regulated in DLB when compared with MA (p < 0.05) (Table 6).
RPL7, RPL21, RPL23A, RPL30, RPL31, RPS5, RPS6, and RPS13 
were upregulated in rpDLB in comparison to MA (p values varied 
from <0.05 to <0.001); RPS16 was downregulated (p <  0.05) 
(Table 6). Due to similar trends of gene expression in DLB and 
rpDLB, only RPS6 and RPS13 were significantly upregulated 
(p values ranged from <0.05 to <0.001) in rpDLB when compared 
with DLB (Table 6).
expression of Proteins involved in 
ribosomal Transcription in Ma, DlB, and 
rpDlB
Only eIF5 was significantly reduced in DLB when compared with 
MA cases (p <  0.05). However, the expression levels of initia-
tion factors eIF2α and eIF5 were significantly decreased in 
rpDLB when compared with MA cases (p < 0.01 and p < 0.05, 
respectively). eIF2α, p-eIF2α, and eIF3η were significantly 
decreased (p <  0.05) in rpDLB when compared with DLB 
(Figure 3).
In contrast, no alterations in the expression levels of elonga-
tion factors eEF1A and eEF2 were observed in DLB and rpDLB 
when compared with MA cases (Figure 3).
mrna expression levels of cytokines and 
Mediators of the innate inflammatory 
response in Ma, DlB, and rpDlB
No differences in the expression of twenty-three genes encod-
ing cytokines and mediators of the inflammatory response were 
detected in DLB when compared with MA. However, significant 
increase in the levels of TNFα (p < 0.001) and CST7 (p < 0.05) was 
found in rpDLB cases when compared with MA (Table 7). TNFα 
and C1QL1 were significantly upregulated in rpDLB when com-
pared with DLB (p < 0.01 and p < 0.05, respectively) (Table 7).
Microglia and TnFα in Ma, DlB, and 
rpDlB
Western blotting revealed a significant increase in GFAP pro-
tein levels in DLB and rpDLB when compared with MA cases 
(p <  0.01), whereas the levels of Iba-1 were maintained when 
compared with MA cases (Figure 4). TNFα protein levels were 
also significantly increased in rpDLB when compared with MA 
(p < 0.05) (Figure 4).
FigUre 1 | Protein expression in middle-aged (Ma) (n = 12), dementia with lewy bodies (DlB) (n = 9) and rapid DlB (rpDlB) (n = 4) of subunits of 
mitochondrial complexes i (nDUFFa7, nDUFa10, nDUFB10, nDUFs8, nDUFB8), ii (sDhB), iii (UQcrc2), iV (MTcO1), and V (aTP5a, aTP50) 
normalized with both β-actin- and voltage-dependent anion channel (VDac). Three representative cases are shown in western blots. Diagrams show 
quantitative values of all assessed cases. Significant decrease in the expression levels of the majority of these subunits is seen in the frontal cortex in DLB and less 
markedly in rpDLB when compared with MA cases when normalized with β-actin and in most cases with VDAC. Decreased expression of VDAC in DLB probably 
reflects decrease in the number of mitochondria: *p < 0.05, **p < 0.01, and ***p < 0.001.
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mrna expression levels of Olfactory 
receptors (Ors) and Taste receptors 
(Tasrs) in Ma, DlB, and rpDlB
Increased expression of OR2D2, OR4F4, OR11H1, and OR52H1 
was observed in DLB when compared with MA cases (p < 0.05). 
Upregulation of OR2D2 and OR2T33 was significantly higher 
in rpDLB compared with MA (p < 0.05). Significant differences 
between DLB and rpDLB were restricted to OR2T33 and OR4F4 
(p < 0.001 and p < 0.05, respectively) (Table 8).
TAS2R4, TAS2R5, and TAS2R14 were upregulated in DLB 
when compared with MA (p values varied from <0.05 to <0.01). 
TAS2R4, TAS2R5, TAS2R13, and TAS2R14 expression was signifi-
cantly increased in rpDLB in comparison to MA cases (p values 
from <0.05 to <0.001) (Table 8).
soluble aβ40 and aβ42, Membrane-
associated β-amyloid, Tau Oligomeric 
species, and α-synuclein Oligomeric 
species in Total homogenate Fractions
In spite of there being no apparent differences in β-amyloid plaque 
burden in DLB and rpDLB, significant increases in soluble Aβ40 
and Aβ42 levels were seen in rpDLB when compared with DLB 
(p <  0.05 and p <  0.01, respectively) (Figure  5A). Curiously, 
levels in DLB were similar to those in controls. However, no 
differences between DLB and rpDLB were seen regarding 
β-amyloid associated with membranes (Figure  5B), which in 
AD has a close correlation with fibrillar β-amyloid in amyloid 
plaques (78).
Regarding tau pathology, western blots of total homogenates 
disclosed no tau oligomers in frontal cortex in DLB and rpDLB 
(Figure 5C) thus being in accordance with the small quantity of 
NFT in the frontal cortex in the present series.
Finally, α-synuclein oligomers were observed in DLB and 
rpDLB in contrast with the lack of α-synuclein oligomers in MA 
cases. Importantly, the band pattern and the density of the bands 
of oligomers were similar in DLB and rpDLB (Figure 5D).
DiscUssiOn
The present study was undertaken to identify alterations of 
several metabolic pathways, which may participate in age-related 
DLB pathology including mitochondrial function and energy 
metabolism, purine metabolism, protein synthesis machinery, 
TaBle 5 | mrna expression of genes encoding proteins linked to purine metabolism in Ma (n = 12), DlB (n = 9), and rpDlB (n = 4).
Probes Ma DlB rpDlB Ma vs DlB Ma vs rpDlB DlB vs rpDlB
ADA 1.12 ± 0.55 2.09 ± 1.41 2.83 ± 0.57 – *↑ (0.0123) –
AK1 1.03 ± 0.27 1.13 ± 0.53 1.64 ± 0.17 – *↑ (0.0321) –
AK2 1.06 ± 0.35 1.26 ± 0.62 1.72 ± 0.35 – – –
AK4 1.06 ± 0.35 1.96 ± 1.52 2.22 ± 0.73 – – –
AK5 1.09 ± 0.49 0.83 ± 0.37 1.27 ± 0.53 – – –
AK7 1.08 ± 0.48 1.05 ± 0.31 1.29 ± 0.31 – – –
APRT 1.04 ± 0.31 0.79 ± 0.25 0.86 ± 0.28 – – –
DGUOK 1.03 ± 0.26 0.90 ± 0.32 1.31 ± 0.23 – – –
ENTPD1 1.09 ± 0.45 1.55 ± 1.04 2.50 ± 0.09 – *↑ (0.0198) –
ENTPD2 1.01 ± 0.17 0.60 ± 0.19 1.37 ± 0.94 – – *↑ (0.0204)
ENTPD3 1.07 ± 0.42 0.83 ± 0.27 0.92 ± 0.30 – – –
NME1 1.05 ± 0.35 1.66 ± 0.95 2.79 ± 1.11 – **↑ (0.0031) –
NME3 1.04 ± 0.29 1.07 ± 0.38 1.89 ± 0.49 – **↑ (<0.01) **↑ (<0.01)
NME4 1.01 ± 0.18 1.68 ± 1.03 2.55 ± 0.84 – **↑ (0.0033) –
NME5 1.05 ± 0.36 0.71 ± 0.41 1.15 ± 0.19 – – –
NME6 1.03 ± 0.24 1.31 ± 0.19 1.49 ± 0.33 *↑ (<0.05) *↑ (<0.05) –
NME7 1.05 ± 0.34 0.82 ± 0.40 1.08 ± 0.32 – – –
NT5C 1.04 ± 0.30 0.94 ± 0.46 1.24 ± 0.36 – – –
NT5E 1.05 ± 0.34 0.82 ± 0.40 1.08 ± 0.32 – – –
PNP 1.16 ± 0.74 1.94 ± 0.82 2.91 ± 1.72 – *↑ (0.0157) –
POLR3B 1.04 ± 0.29 1.03 ± 0.29 0.98 ± 0.19 – – –
PRUNE 1.01 ± 0.14 1.18 ± 0.26 1.62 ± 0.44 – ***↑ (0.0009) *↑ (<0.05)
Important variations were detected in rpDLB cases when compared with MA. Changes are represented with the corresponding p-value and mRNA levels are expressed as mean 
fold change ± SD determined by RT-qPCR and analyzed with the ΔΔCT method: *p < 0.05, **p < 0.01, and ***p < 0.001.
FigUre 2 | Mitochondrial enzymatic activities in complex i, ii, iii, iV, and V in middle-aged (Ma), dementia with lewy bodies (DlB), and rapid DlB 
(rpDlB). All the mitochondrial activities are corrected with the appropriate values of citrate synthase for each sample. Significant decreased activity of complex I, II, 
III, and IV is observed in DLB and rpDLB when compared with MA. Complex V activity showed a trend toward reduction in DLB and rpDLB: *p < 0.05, **p < 0.01, 
***p < 0.001.
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inflammation and certain recently discovered new ectopic ORs 
and TASRs expressed in brain.
The focus of the study was to learn about biochemical altera-
tions beyond the well-known modifications of target proteins in 
DLB such as α-synuclein and β-amyloid. Present biochemical 
studies have shown similar percentages of Aβ40 and Aβ42 in 
plaques in DLB and rpDLB abnormal solubility and aggregation 
of α-synuclein and increased β-amyloid bound to membranes 
in the frontal cortex in DLB and rpDLB. In contrast, no differ-
ences in tau oligomers were found between MA and DLB cases. 
TaBle 6 | mrna expression levels of genes encoding nucleolar proteins, ribosomal proteins, and 18s and 28s rrnas in Ma (n = 12), DlB (n = 9), and 
rpDlB (n = 4).
Probes Ma DlB rpDlB Ma vs DlB Ma vs rpDlB DlB vs rpDlB
nucleolar proteins
NPM1 1.07 ± 0.45 0.60 ± 0.11 0.71 ± 0.24 *↓ (0.0246) – –
NCL 1.075 ± 0.446 0.70 ± 0.17 0.78 ± 0.27 – – –
UBTF 1.07 ± 0.43 0.72 ± 0.17 0.83 ± 0.40 – – –
rrna
rRNA18S 1.04 ± 0.28 1.22 ± 0.41 2.12 ± 0.66 – **↑ (0.0015) **↑ (<0.01)
rRNA28S 1.12 ± 0.62 1.01 ± 0.25 1.34 ± 1.12 – – –
ribosomal proteins
Large subunit RPL5 1.10 ± 0.14 0.99 ± 0.16 1.23 ± 0.25 – – –
RPL7 1.01 ± 0.12 1.19 ± 0.15 1.38 ± 0.20 *↑ (<0.05) **↑ (0.0014) –
RPL21 1.03 ± 0.29 2.10 ± 0.65 2.72 ± 0.77 **↑ (<0.01) ***↑ (<0.0001) –
RPL22 1.01 ± 0.17 0.78 ± 0.18 0.83 ± 0.20 *↓ (0.0305) – –
RPL23A 1.04 ± 0.31 1.41 ± 0.28 1.71 ± 0.46 – *↑ (<0.05) –
RPL26 1.02 ± 0.21 0.76 ± 0.34 0.71 ± 0.22 – – –
RPL27 1.01 ± 0.15 1.04 ± 0.11 1.23 ± 0.34 – – –
RPL30 1.03 ± 0.26 1.55 ± 0.34 2.05 ± 0.31 **↑ (<0.01) *** ↑ (<0.0001) –
RPL31 1.01 ± 0.15 1.21 ± 0.25 1.55 ± 0.29 – **↑ (0.0026) –
Small subunit RPS3A 1.03 ± 0.25 1.36 ± 0.40 1.26 ± 0.22 – – –
RPS5 1.01 ± 0.11 1.20 ± 0.17 1.31 ± 0.19 *↑ (<0.05) *↑ (<0.05) –
RPS6 1.01 ± 0.17 1.14 ± 0.10 1.70 ± 0.40 – ***↑ (0.0002) **↑ (<0.01)
RPS10 1.02 ± 0.23 1.04 ± 0.19 1.17 ± 0.30 – – –
RPS13 1.01 ± 0.16 1.04 ± 0.11 1.35 ± 0.30 – *↑ (<0.05) *↑ (<0.05)
RPS16 1.04 ± 0.29 0.75 ± 0.29 0.52 ± 0.01 – *↓ (0.0166) –
RPS17 1.01 ± 0.11 0.90 ± 0.06 1.10 ± 0.28 – – –
RPS20 1.01 ± 0.13 0.92 ± 0.14 0.96 ± 0.20 – – –
Changes are represented with the corresponding p-value and mRNA levels are expressed as mean fold change ± SD determined by RT-qPCR and analyzed with the ΔΔCT method: 
*p < 0.05, **p < 0.01, and ***p < 0.001.
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Whether levels of soluble Aβ40 and Aβ42 are within control 
values in DLB in spite of the presence of plaques (73, 74) needs 
further study.
Mitochondria and energy Metabolism
Mitochondrial alterations in the frontal cortex are prominent in 
DLB. ATP5G2 and ATP5H expression is decreased in DLB when 
compared with MA individuals; protein expression of NDUFA7, 
NDUFA10, NDUFB8, SDHB, UQCRC2, MTCO1, ATP5A, 
and ATP50 is reduced. No differences in expression are found 
in rpDLB in contrast to DLB. NDUFA7 protein levels are sig-
nificantly reduced in rpDLB and significant differences between 
DLB and rpDLB are restricted to NDUFB8, SDHB, ATP5A, 
and ATP50. It is worth stressing that these alterations are not 
the mere consequence of mitochondrial loss in DLB. Expression 
levels of VDAC are decreased in DLB but the expression levels 
of the mentioned subunits are reduced even considering VDAC 
for normalization of protein levels. It can be argued that the 
rapid course of the disease results in a reduced harmful impact 
on mitochondria in rpDLB when compared with DLB. Despite 
differences in gene and protein expression, mitochondrial 
enzymatic activity of complexes I, II, III, and IV is significantly 
decreased in frontal cortex area 8 in DLB and rpDLB. Therefore, 
the present observations point to altered mitochondrial function 
in frontal cortex as a major factor in the pathogenesis of DLB 
and rpDLB.
Regarding energy metabolism, ATP4A and SLC6A6 are 
upregulated in DLB, while ATP6V0B is downregulated in 
DLB and rpDLB. TOMM40 is downregulated in rpDLB 
ATP4A encodes a membrane-bound P-type ATPase, which 
permits ion transport through cell membranes (79). SLC6A6 
encodes a taurine transporter (SLc6a6/TauT) involved in the 
uptake of gamma-aminobutyric acid (GABA) (80). Whether 
these changes have implications in GABA metabolism in 
DLB is not known although GABA levels in the CSF in DLB 
are not altered when compared with normal individuals (81). 
ATP6V0B encodes ATPase H+ transporting Vo subunit b, 
which is involved in protein sorting, zymogen activation, 
receptor-mediated endocytosis, and synaptic vesicle proton 
gradient generation (82). TOMM40 encodes a translocase of 
outer mitochondrial membrane which is required for protein 
transfer into mitochondria (83). Together, these results suggest 
energy metabolism impairment in frontal cortex in DLB and 
rpDLB.
Purine Metabolism
Several genes encoding enzymes linked to purine metabolism 
are upregulated in DLB and rpDLB although significant values 
are only obtained when comparing rpDLB with MA cases. These 
include ADA, AK1, ENTPD1, NME1, NME3, NME4, NME6, PNP, 
and PRUNE. However, only three genes, ENTPD2, NME3, and 
PRUNE, are significantly upregulated in rpDLB when compared 
with DLB.
Purines and pyrimidines are the core of DNA, RNA, nucleo-
sides, and nucleotides. Nucleotides are involved in cell signaling 
and energy metabolism, and purine bases are also cofactors of 
FigUre 3 | Protein expression, as revealed by western blotting, of initiation and elongation factors of protein transcription at the ribosome in Ma 
(n = 12), dementia with lewy bodies (DlB) (n = 9) and rapid DlB (rpDlB) (n = 4) using β-actin for normalization. Reduced expression of initiation factors 
is more marked in rpDLB than in DLB, whereas the expression of elongation factors eEF1A and eEF2 is not modified in DLB and rpDLB: *p < 0.05, **p < 0.01, and 
***p < 0.001.
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several enzymatic reactions (84–87). Adenylate kinases partici-
pate in the phosphorylation of AMP to ADP and dAMP to dATP 
(88, 89). The NME gene family encodes nucleotide diphosphate 
kinases, which are involved in the phosphorylation of nucleotide 
diphosphates to form nucleotide triphosphates. These enzymes 
are enriched in synapses. Increased NME mRNA expression in 
DLB contrasts with its decrease in AD (90, 91) and suggests a 
compensatory role of NME in response to reduced synapses in 
DLB. The product of PRUNE participates in the metabolism of 
guanosine pentaphosphate and tetraphosphate and is linked 
to NME in memory conservation (92). Deoxyguanosine 
kinase (encoded by DGUOK) phosphorylates purine deoxyri-
bonucleosides in the mitochondrial matrix (93–95). Adenine 
phosphoribosyltransferase is related to adenine metabolism 
and catalyses the phosphorylation reaction, whereas ADA de-
aminates adenosine.
Furthermore, ectonucleoside triphosphate diphosphohy-
drolases, encoded by ENTPD genes, hydrolyze the terminal 
phosphate group of nucleoside tri- and diphosphates to form 
di- and monophosphates, thus controlling extracellular ATP 
concentrations (96), adenosine-activated type I receptors, 
nucleotide-activated type 2 ligand-gated ion channels, and 
metabotropic P2Y receptors (97). Finally, ecto 5′-nucleotidase 
catalyzes the generation of adenosine from degradation of AMP 
in the extracellular space. In brain, ectonucleotidases are involved 
in several functions including modulation of synaptic transmis-
sion, ATP-mediated propagation of calcium waves in glial cells, 
neurogenesis, microglial function, and blood flow (98).
Present findings show marked alterations in the expression of 
enzymes involved in purine metabolism in the frontal cortex in 
DLB and rpDLB.
Protein synthesis
Decreased expression of NPM1 is found in the frontal cortex in 
DLB, which may be indicative of nucleolar stress and linked to 
altered ribosomal biogenesis (99–103).
Alterations in the expression of genes encoding ribosomal 
proteins are seen in DLB and rpDLB, including up- and down-
regulation of RPLs, thus suggesting impaired ribosome biogenesis 
(104–107). This is accompanied by reduced protein expression of 
several initiation factors of transcription at the ribosome, which 
are more marked in rpDLB than in DLB. However, the expres-
sion levels of elongation factors eEF1A and eEF2 are preserved in 
DLB and rpDLB. Although the direct study of protein synthesis is 
not possible in human postmortem samples due to postmortem 
delay between death and tissue processing, the present findings 
indicate that the machinery of protein synthesis is altered in DLB 
(108–110). Importantly, altered expression of proteins involved 
in transcription at the ribosome is more severe in rpDLB than 
in DLB.
inflammatory responses
No significant differences in gene expression of several cytokines 
and mediators of the inflammatory response are seen in DLB. 
These data are in line with the observation of no major increase in 
Iba1 protein levels and CD68 expression in frontal cortex in DLB 
when compared with MA individuals. They are also in agreement 
with previous observations showing very limited activation of 
microglia in DLB (111, 112).
Subtle change refers to TNFα gene expression in rpDLB. 
Whereas TNFα mRNA is not altered in DLB, significant TNFα 
mRNA upregulation and increased TNFα protein levels occur 
in the frontal cortex in rpDLB. TNFα is involved in several 
FigUre 4 | TnFα, gFaP, and iba-1 protein levels in middle-aged (Ma), dementia with lewy bodies (DlB), and rapid DlB (rpDlB) as revealed by 
western blotting using β-actin for normalization. Significant increased GFAP expression occurs in DLB and rpDLB when compared with MA (p < 0.01). A 
significant increase also occurs in TNFα levels in rpDLB when compared with MA (p < 0.05): *p < 0.05, **p < 0.01, and ***p < 0.001.
TaBle 7 | mrna expression levels of genes encoding cytokines and mediators of the innate inflammatory response in Ma (n = 12), DlB (n = 9), and 
rpDlB (n = 4).
Probes Ma DlB rpDlB Ma vs DlB Ma vs rpDlB DlB vs rpDlB
anti-inflammatory cytokines
IL10 family IL10 1.36 ± 0.99 0.70 ± 0.38 1.37 ± 0.97 – – –
IL10RA 1.13 ± 0.61 0.84 ± 0.29 1.40 ± 0.66 – – –
IL10RB 1.04 ± 0.29 0.85 ± 0.29 1.24 ± 0.60 – – –
TGF family TGFB1 1.11 ± 0.50 0.93 ± 0.39 1.40 ± 0.55 – – –
TGFB2 1.08 ± 0.46 1.28 ± 0.46 1.40 ± 0.48 – – –
Pro-inflammatory cytokines
IL6 1.20 ± 0.78 1.18 ± 0.99 3.25 ± 2.87 – – –
IL6ST 1.04 ± 0.31 0.92 ± 0.18 1.33 ± 0.44 – – –
IL8 1.12 ± 0.60 1.37 ± 0.83 1.39 ± 0.73 – – –
IL1β 1.61 ± 1.57 1.50 ± 1.81 1.22 ± 0.71 – – –
TNFα family TNFα 1.14 ± 0.57 1.52 ± 0.51 4.28 ± 1.28 – ***↑ (0.0005) **↑ (<0.01)
TNFRSF1A 1.08 ± 0.41 1.57 ± 1.06 1.60 ± 0.84 – – –
inflammation mediators
TLRs TLR4 1.06 ± 0.38 1.56 ± 1.11 1.74 ± 0.99 – – –
TLR7 1.36 ± 1.04 0.83 ± 0.57 1.21 ± 0.52 – – –
Colony-stimulating factors CSF1R 1.15 ± 0.55 0.80 ± 0.43 1.12 ± 0.29 – – –
CSF3R 1.24 ± 0.79 1.14 ± 0.65 2.21 ± 0.44 – – –
Complement system C1QL1 1.04 ± 0.31 0.95 ± 0.27 1.74 ± 0.99 – – *↑ (0.0366)
C3AR1 1.27 ± 0.87 0.97 ± 0.66 2.22 ± 1.61 – – –
C1QTNF7 1.15 ± 0.64 0.85 ± 0.37 0.97 ± 0.49 – – –
Cathepsins CTSC 1.37 ± 1.25 0.86 ± 0.54 0.92 ± 0.09 – – –
CTSS 1.36 ± 1.24 0.91 ± 0.53 1.11 ± 0.46 – – –
Integrin family & ITGB2 1.33 ± 0.97 0.98 ± 0.62 1.73 ± 1.04 – – –
CTL/CTLD superfamily CLEC7A 1.24 ± 0.76 0.95 ± 0.46 1.11 ± 0.39 – – –
CST7 1.44 ± 1.17 2.77 ± 1.89 4.46 ± 1.99 – *↑ (0.0307) –
Changes are represented with the corresponding p-value and mRNA levels are expressed as mean fold change ± SD determined by RT-qPCR and analyzed with the ΔΔCT method: 
*p < 0.05, **p < 0.01, and ***p < 0.001.
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metabolic pathways, particularly facilitating gene transcription, 
activating of the JNK pathway and promoting apoptosis via 
caspase-dependent and caspase-independent signaling (113). 
Therefore, TNFα upregulation in rpDLB may have functional 
implications. Further molecular studies are needed to elucidate 
activated molecules of the TNFα pathways in rpDLB.
Olfactory and Taste Brain receptors
Olfactory and taste receptors are widely expressed in human and 
rodent brain including the cerebral cortex. ORs and TASRs in 
brain are accompanied by all downstream molecules that permit a 
functional signaling pathway, and they are functional, as revealed 
in culture neurons under appropriate stimuli (114, 115).
The expression of several genes encoding ORs is increased in 
DLB and rpDLB. Three out of six TASR are upregulatred in DLB 
and four genes in rpDLB.
The function of ORs and TASRs in brain is not known 
although it has been postulated that they may participate in 
intra- and extracellular signaling in association, or not, with 
other receptors. Identification of natural ligands of brain ORs 
and TASRs should yield insights about the function of these 
ectopic receptors (114).
TaBle 8 | mrna expression levels of genes encoding olfactory receptors (Ors) and taste receptors (Tasrs) in Ma (n = 12), DlB (n = 9), and rpDlB 
(n = 4).
Probes Ma DlB rpDlB Ma vs DlB Ma vs rpDlB DlB vs rpDlB
Ors
OR2D2 1.30 ± 0.77 3.39 ± 2.57 4.94 ± 0.89 *↑ (<0.05) **↑ (0.0018) –
OR2J3 1.13 ± 0.54 1.10 ± 0.55 1.55 ± 0.83 – – –
OR2L13 1.36 ± 0.86 1.22 ± 0.88 1.09 ± 0.92 – – –
OR2T1 1.09 ± 0.49 1.63 ± 0.97 1.71 ± 0.35 – – –
OR2T33 1.24 ± 0.83 0.80 ± 0.38 3.60 ± 1.44 – **↑ (0.01) ***↓ (0.0004)
OR4F4 1.20 ± 0.52 2.22 ± 1.09 0.80 ± 0.32 *↑ (<0.05) – *↓ (0.05)
OR6F1 1.02 ± 0.22 1.63 ± 1.40 2.14 ± 0.86 – – –
OR10G8 1.11 ± 0.53 1.23 ± 0.44 0.67 ± 0.21 – – –
OR11H1 1.07 ± 0.37 3.15 ± 2.37 2.26 ± 0.74 *↑ (0.0236) – –
OR51E1 1.11 ± 0.49 1.94 ± 1.57 1.83 ± 0.96 – – –
OR52H1 1.18 ± 0.65 3.60 ± 3.00 4.25 ± 1.25 *↑ (0.0256) – –
OR52L1 1.05 ± 0.35 1.66 ± 1.14 1.06 ± 1.02 – – –
OR52M1 1.09 ± 0.52 1.10 ± 0.87 1.84 ± 0.36 – – –
Tasr
TAS2R4 1.03 ± 0.27 1.82 ± 0.78 2.16 ± 0.78 *↑ (<0.05) **↑ (0.0029) –
TAS2R5 1.03 ± 0.25 2.25 ± 1.03 2.12 ± 0.33 **↑ (0.0013) *↑ (<0.05) –
TAS2R10 1.13 ± 0.50 1.68 ± 0.64 1.88 ± 0.44 – – –
TAS2R13 1.11 ± 0.49 1.63 ± 0.62 1.99 ± 0.06 – *↑ (0.0201) –
TAS2R14 1.15 ± 0.57 2.51 ± 1.59 4.14 ± 1.16 *↑ (<0.05) ***↑ (0.0004) –
TAS2R50 1.08 ± 0.40 1.54 ± 1.15 2.34 ± 1.16 – – –
Changes are represented with the corresponding p-value, and mRNA levels are expressed as mean fold change ± SD determined by RT-qPCR and analyzed with the ΔΔCT 
method: *p < 0.05, **p < 0.01, and ***p < 0.001.
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Mitochondrial Function, inflammation, and 
Deregulation of Ors and Tasrs in Frontal 
cortex Discriminate DlB and aD
The present study reveals disease-specific alterations when com-
paring the present results in DLB with available data for AD in 
the same region, the frontal cortex, at similar stages of disease 
progression.
Mitochondrial alterations and impaired activity of complex V 
are early events in the entorhinal cortex in AD (116). NDUFA2, 
NDUFB3, UQCR11, COX7C, ATPD, ATP5L, and ATP50 gene 
expression is reduced in the entorhinal cortex with disease 
progression, and this is accompanied by impaired activity of 
complexes I, II, and V (72). In contrast, RNA expression levels 
of several subunits of complexes I–V and enzymatic activities of 
complex I, II, IV, and V are preserved in frontal cortex in AD even 
at stages V–VI of Braak in individuals with mean ages similar 
to those of assessed DLB cases (72). Therefore, mitochondrial 
dysfunction in frontal cortex markedly differs in AD and DLB, 
with detrimental effects in most mitochondrial complexes in DLB 
in comparison with AD.
There is a large body of information demonstrating microglial 
responses and increased expression of inflammatory markers in 
the cerebral cortex in AD (73, 74, 117–131). In contrast, inflam-
matory responses are very limited in DLB. Therefore, inflamma-
tion is characteristically an important factor in AD pathogenesis, 
whereas it has low impact in DLB.
Regarding purine metabolism, ENTPD2, NME3, PNP, and 
PRUNE RNAs are deregulated in the frontal cortex in AD (91), 
whereas ADA, AK1, ENTPD1, NME1, NME3, NME4, NME6, 
PNP, and PRUNE are upregulated in rpDLB with changes less 
marked in DLB.
Severe alterations of the machinery involved in protein syn-
thesis from the nucleolus to the ribosome have been observed 
in the entorhinal cortex in AD (132), but no similar data are 
available in AD frontal cortex.
Finally, OR4F4 mRNA expression levels are increased in frontal 
cortex area 8 at stages III–IV, and OR52L1 mRNA at Braak stages 
III–IV and V–VI in AD (133). Regarding TASRs, no modification 
in the mRNA expression levels is observed in frontal cortex area 8 
at any stage of AD (133). These observations in AD are in contrast 
with the extensive deregulation of ORs and TASRs in the frontal 
cortex in DLB, thus indicating marked differences in the regula-
tion of these brain receptors in DLB when compared with AD.
specific Traits in rpDlB compared  
with DlB
No neuropathological differences are seen between DLB and 
rpDLB in accordance with other studies (58). Moreover, rpDLB 
has similar biochemical profiles regarding mitochondrial gene 
and protein expression, protein synthesis, and expression of ORs 
and TASRs. However, gene and protein expression of subunits 
of mitochondrial respiratory complexes are more pronounced in 
DLB when compared with rpDLB, whereas alterations in purine 
metabolism and initiation of protein translation are more pro-
nounced in rpDLB when compared with DLB. Due to the small 
number of rpDLB cases available for biochemical studies, these 
observations need further validation.
Two additional traits which differentiate rpDLB and DLB 
merit a comment. The first of these is the higher levels of soluble 
Aβ40 and Aβ42 in rpDLB in spite of similar plaque burden and 
β-amyloid associated with membranes in rpDLB when compared 
with DLB. In this line, modified characteristics of Aβ42 have been 
FigUre 5 | soluble aβ40 and aβ42, membrane-associated β-amyloid, tau oligomers, and α-synuclein oligomeric species in total homogenate 
fractions in middle-aged (Ma) (n = 10), dementia with lewy bodies (DlB) (n = 10) and rapid DlB (rpDlB) (n = 4). (a) Soluble Aβ40 and Aβ42 levels are 
similar in MA and DLB cases but soluble Aβ40 and Aβ42 are significantly increased in rpDLB when compared with MA and DLB; (B) membrane-associated 
β-amyloid is detected in DLB and rpDLB but not in MA cases as revealed with human amyloid-beta protein antibodies 4G8 and 6E10; (c) no tau oligomers are 
detected in DLB and rpDLB even after membrane over-exposition; (D) α-synuclein oligomers are present equally in DLB and rpDLB, which is in contrast with the 
lack of α-synuclein oligomers in MA. The figures are representative of four MA, four DLB, and four rpDLB; statistical values represent the totality of samples: 
*p < 0.05, **p < 0.01, and ***p < 0.001.
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described in rapidly progressive AD (134), thus suggesting that 
β-amyloid conformers pace disease progression in AD. It can be 
suggested that higher levels of soluble β-amyloid oligomeric spe-
cies, known to be toxic to nerve cells (135–140), can precipitate 
disease progression in rpDLB. The second differential aspect is 
the higher levels of TNFα in rpDLB when compared with DLB, 
which can also be toxic to nerve cells.
cOnclUsiOn
Molecular alterations in the cerebral cortex in DLB include (i) 
deregulated expression of several mRNAs and proteins of mito-
chondrial subunits and reduced activity of complexes I, II, III, and 
IV of the mitochondrial respiratory chain; (ii) reduced expres-
sion of selected molecules involved in energy metabolism and 
increased expression of enzymes involved in purine metabolism; 
(iii) abnormal expression of certain nucleolar proteins, rRNA18S, 
genes encoding ribosomal proteins and initiation factors of the 
transcription at the ribosome; (iv) discrete inflammation; and (v) 
marked deregulation of brain ORs and TASRs. Severe mitochon-
drial dysfunction involving activity of four complexes, minimal 
inflammatory responses, and dramatic altered expression of ORs 
and TASRs discriminate DLB from AD. Altered solubility and 
aggregation of α-synuclein, increased β-amyloid bound to mem-
branes, and absence of soluble tau oligomers are common in DLB 
and DLB with rapid progression. Increased soluble β-amyloid 
1–40 and β-amyloid 1–42, and increased TNFα mRNA and 
protein expression, distinguish DLB with rapid progression from 
typical DLB. Since high levels of soluble β-amyloid species are 
toxic for nerve cells and TNF-α.
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